The biotech firm AXIM Biotechnologies Inc. AXIM reports that it has developed fast, point-of-care tests to help eye doctors detect dry eye syndrome, a big issue in today’s world. It is important to differentiate from simple allergies for proper care and treatment. Up to this point, testing was a much slower and involved process, delaying proper diagnosis and causing prolonged suffering in patients.

AXIM says it has delivered a Food and Drug Administration (FDA)-cleared rapid test that doesn’t require much tearing to work, which makes it easy to administer.

Bites By The Numbers:

  • The test is completed in just eight minutes.
  • The dry eye market is expected to reach $6.1 billion by 2024.
  • 20 million people in the U.S. have dry eye syndrome.

AXIM looks to deliver these tests to U.S. doctors, who are eligible for Medicare (CMS) and insurance reimbursement and hopefully will provide relief for millions of Americans suffering from chronic ailments.